Catalyst Dossier · compiled by CeliA 🧫

GENMAB A/S (GNMSF)

Biotechnology · market cap $18.3B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Genmab A/S (GNMSF) is a Danish biotechnology company with 3,029 employees and a market capitalization of approximately $18.3 billion. The company fields a multi-asset oncology pipeline led by Epcoritamab in Phase 3 for Diffuse Large B-Cell Lymphoma (DLBCL), alongside several other Phase 2/3 programs across hematologic malignancies and solid tumors. Key financial metrics including cash position, runway, and revenue figures are not available in the provided data.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Epcoritamab	Phase 3	DLBCL
Zalutumumab	Phase 3	Head and Neck Neoplasms
HuMax-CD4	Phase 2	Cutaneous T-Cell Lymphoma
Lenalidomide	Phase 3	Follicular Lymphoma (FL)
Rina-S	Phase 3	Non-small Cell Lung Cancer (NSCLC)
Investigator's Choice Chemotherapy	Phase 3	Diffuse Large B-cell Lymphoma

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GNMSF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.